A5018221472- Complement system in diseases
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Blood Pressure and Hypertension Studies
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
- COVID-19 Clinical Research Studies
- Cardiovascular Health and Disease Prevention
- Renal Transplantation Outcomes and Treatments
- Platelet Disorders and Treatments
- Renal Diseases and Glomerulopathies
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- SARS-CoV-2 and COVID-19 Research
- Atherosclerosis and Cardiovascular Diseases
- Heart Rate Variability and Autonomic Control
- Cardiovascular Disease and Adiposity
- COVID-19 and healthcare impacts
- Systemic Lupus Erythematosus Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Rheumatoid Arthritis Research and Therapies
- Long-Term Effects of COVID-19
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
Aristotle University of Thessaloniki
2016-2025
G. Papanikolaou General Hospital
2016-2025
Papageorgiou General Hospital
2015-2025
Hippocration General Hospital
2023-2025
Inserm
2023
Centre de recherche en Epidémiologie et Santé des Populations
2023
Université Paris-Saclay
2023
Centre Hospitalier Sud Francilien
2023
Hospital Universitario Infanta Leonor
2023
Universität Hamburg
2023
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation the alternative pathway complement that treated with eculizumab, a humanized monoclonal antibody against terminal component C5. Eculizumab must be administered intravenously, moreover some patients paroxysmal on eculizumab have symptomatic extravascular hemolysis, indicating an unmet need for additional therapeutic approaches. We report activity two novel small-molecule inhibitors...
There is an unmet need of models for early prediction morbidity and mortality Coronavirus disease-19 (COVID-19). We aimed to a) identify complement-related genetic variants associated with the clinical outcomes ICU hospitalization death, b) develop artificial neural network (ANN) predicting these c) validate whether are impaired complement phenotype. prospectively recruited consecutive adult patients Caucasian origin, hospitalized due COVID-19. Through targeted next-generation sequencing, we...
The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. aim present study was to retrospectively analyse the and risk factors for mortality a large series patients who developed infection after an HSCT.This multicenter retrospective promoted by European Hematology Association - Infections Study Working Group, included 326 adult HSCT had between January 2020 March 2022.The median time from diagnosis 268 days (IQR...
Abstract Complement inhibition has shown promise in various disorders, including COVID‐19. A prediction tool complement genetic variants is vital. This study aims to identify crucial complement‐related and determine an optimal pattern for accurate disease outcome prediction. Genetic data from 204 COVID‐19 patients hospitalized between April 2020 2021 at three referral centres were analysed using artificial intelligence‐based algorithm predict (ICU vs. non‐ICU admission). recently introduced...
Although impairment of the micro- and macrocirculation is considered inherent to sustained hypertension, there a substantial lack studies investigating whether an association exists between macrovascular damage, especially in early-stage hypertension. We studied meticulously selected population, free diabetes cardiovascular disease, 223 individuals: 137 never-treated, newly diagnosed patients with recent onset hypertension 86 normotensive individuals. Nonmydriatic retinal photography was...
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe and life-threatening complication of hematopoietic cell transplantation (HCT) that often coincides with graft-versus-host-disease (GVHD). Although endothelial damage seems to be the common denominator for both disorders, role complement system, neutrophils, coagulation has not been clarified. In an effort distinguish pathogenesis TA-TMA from GVHD, we evaluated markers activation, neutrophil extracellular trap (NET)...
Abstract Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has great impact and previously been shown cause high mortality in this population. Until now, real-world data on the of vaccination treatment patients COVID-19 after CAR are lacking. Therefore, multicenter, retrospective study was conducted from EPICOVIDEHA survey. Sixty-four were identified. The overall caused...
Abstract Ruxolitinib has become the new standard of care for steroid-refractory and steroid-dependent chronic GVHD (SR-cGVHD). Our aim was to collect comparative data between ruxolitinib extracorporeal photophoresis (ECP). We asked EBMT centers if they were willing provide detailed information on grading, -therapy, -dosing, -response complications each included patient. 31 responded positively we all patients 1/2017-7/2019 treated with ECP or moderate severe SR-cGVHD. identified 84 57...
Abstract Renewed interest has emerged in transplant‐associated thrombotic microangiopathy ( TA ‐ TMA ) with novel prognostic, diagnostic, and treatment algorithms. We aimed to investigate the incidence, prognostic factors, morbidity, mortality of allogeneic hematopoietic cell transplantation HCT recipients. enrolled consecutive recipients (1990‐2017). Among 758 patients, 116 (15.5%) were diagnosed . In multivariate analysis, TBI ‐based conditioning, viral infections, acute chronic GVHD...